FDA Requires Testosterone Products to have a General Venous Blood Clot Warning Label

Zoll, Kranz & Borgess, LLC currently represents clients with injuries allegedly caused by testosterone therapy. Toledo, OH (PRWEB) July 03, 2014 The FDA is now requiring all testosterone replacement therapy products to have the general warning that these drugs may cause blood clots in the veins (Venous Thromboembolism (VTE)). Currently, the VTE warning is directly linked to polycythemia, which is when there is an increase in the number of red blood cells. Announced by the FDA June 19, 2014, the more general warning is now required as a result of post market reports that venous bloo
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories